Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia.

IF 3.4 Q2 PHARMACOLOGY & PHARMACY

Australian Prescriber Pub Date : 2023-08-01 DOI:10.18773/austprescr.2023.011

引用次数: 0

查看原文本刊更多论文

新药:Brexucabtagene自体甲醇治疗套细胞淋巴瘤、b细胞急性淋巴细胞白血病

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian Prescriber MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY

CiteScore

3.80

自引率

7.40%

发文量

审稿时长

>12 weeks

期刊介绍： Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online. Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information. As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas. We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.